AR039846A1 - Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo - Google Patents

Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo

Info

Publication number
AR039846A1
AR039846A1 ARP030101782A ARP030101782A AR039846A1 AR 039846 A1 AR039846 A1 AR 039846A1 AR P030101782 A ARP030101782 A AR P030101782A AR P030101782 A ARP030101782 A AR P030101782A AR 039846 A1 AR039846 A1 AR 039846A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
molecula
muc
codifying
vivo
Prior art date
Application number
ARP030101782A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR039846A1 publication Critical patent/AR039846A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se refiere a unas construcciones nuevas de ácidos nucleicos, útiles en los protocolos de vacunación de ácidos nucleicos para el tratamiento y profilaxis de tumores que expresan MUC-1. En particular, el ácido nucleico es DNA y las construcciones de DNA comprenden un gen que codifica un derivado de MUC-1 que tiene menos de 10 unidades de repetición perfectas. La invención además proporciona composiciones farmacéuticas que comprenden dichas construcciones, particularmente composiciones farmacéuticas adaptadas para el suministro mediado por partícula, procedimientos para producirlos, y su uso en medicina. También se proporcionan proteínas nuevas codificadas por el ácido nucleico y composiciones farmacéuticas que las contienen.
ARP030101782A 2002-05-24 2003-05-22 Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo AR039846A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0212046.7A GB0212046D0 (en) 2002-05-24 2002-05-24 Vaccines

Publications (1)

Publication Number Publication Date
AR039846A1 true AR039846A1 (es) 2005-03-02

Family

ID=9937394

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101782A AR039846A1 (es) 2002-05-24 2003-05-22 Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo

Country Status (20)

Country Link
US (1) US20060251665A1 (es)
EP (1) EP1527177A2 (es)
JP (1) JP2005526520A (es)
KR (1) KR20050004211A (es)
CN (1) CN100408682C (es)
AR (1) AR039846A1 (es)
AU (1) AU2003240729B2 (es)
BR (1) BR0311211A (es)
CA (1) CA2485816A1 (es)
GB (1) GB0212046D0 (es)
IL (1) IL165156A0 (es)
IS (1) IS7526A (es)
MX (1) MXPA04011527A (es)
NO (1) NO20044947L (es)
NZ (1) NZ536668A (es)
PL (1) PL374569A1 (es)
RU (1) RU2303069C2 (es)
TW (1) TW200407426A (es)
WO (1) WO2003100060A2 (es)
ZA (1) ZA200409445B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
EP1694364B1 (en) * 2003-11-12 2014-04-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services System for treating and preventing breast cancer
JP5285855B2 (ja) 2003-11-12 2013-09-11 アメリカ合衆国 膵癌を処置および予防するためのカスタムベクター
JP2008528623A (ja) * 2005-01-28 2008-07-31 ラモット アット テル アビブ ユニバーシティ， リミテッド 抗ＭＵＣ１のα／β抗体
US20120039984A1 (en) 2008-07-03 2012-02-16 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
CN106215179A (zh) * 2010-06-11 2016-12-14 乔治亚大学研究基金公司 免疫原性疫苗
CN103209701B (zh) * 2010-06-11 2016-08-03 乔治亚大学研究基金公司 免疫原性疫苗
AU2012222188A1 (en) * 2011-02-24 2013-08-15 Oncothyreon Inc. MUC1 based glycolipopeptide vaccine with adjuvant
CN108778321A (zh) * 2016-01-19 2018-11-09 辉瑞公司 癌症疫苗
AU2017336269B2 (en) * 2016-09-28 2022-06-16 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
TWI825098B (zh) 2018-05-18 2023-12-11 德商葛萊高托普公司 抗ｍｕｃ１抗體

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2282300C (en) * 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
CA2383737C (en) * 1999-09-08 2011-01-18 Transgene S.A. Muc-1 derived peptides
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
EP1257565A4 (en) * 2000-02-01 2005-04-06 Austin Research Inst DERIVED FROM MUCIN-1 ANTIGENE AND ITS USE IN IMMUNOTHERAPY
US20020142047A1 (en) * 2001-01-19 2002-10-03 Johnson Mark E. Microsphere delivery of mucin peptides
US7125663B2 (en) * 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
EP1572918B1 (en) * 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines

Also Published As

Publication number Publication date
CN100408682C (zh) 2008-08-06
PL374569A1 (en) 2005-10-31
AU2003240729B2 (en) 2007-12-20
EP1527177A2 (en) 2005-05-04
AU2003240729A1 (en) 2003-12-12
IL165156A0 (en) 2005-12-18
NO20044947D0 (no) 2004-11-12
KR20050004211A (ko) 2005-01-12
CA2485816A1 (en) 2003-12-04
NZ536668A (en) 2007-01-26
NO20044947L (no) 2005-12-16
US20060251665A1 (en) 2006-11-09
RU2303069C2 (ru) 2007-07-20
MXPA04011527A (es) 2005-09-30
ZA200409445B (en) 2006-02-22
RU2004134331A (ru) 2005-08-27
GB0212046D0 (en) 2002-07-03
WO2003100060A2 (en) 2003-12-04
BR0311211A (pt) 2005-03-01
CN1668746A (zh) 2005-09-14
JP2005526520A (ja) 2005-09-08
TW200407426A (en) 2004-05-16
WO2003100060A3 (en) 2004-02-19
IS7526A (is) 2004-11-11

Similar Documents

Publication Publication Date Title
AR039846A1 (es) Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
BR9712852A (pt) Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
AR047392A1 (es) Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
ATE510011T1 (de) Neue pilzproteine und diese codierende nukleinsäuren
CY1105685T1 (el) Συνδεομενα με ογκους αντιγονικα παραγωγα απο την οικογενεια mage, και ακολουθιες νουκλεϊκων οξεων που τα κωδικοποιουν, χρησιμοποιουμενα στην παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο
DE60035337D1 (de) Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoide Tumorzellen, herbeiführen oder bewirken
WO2004067706A3 (en) Production of multimeric proteins
CL2009000648A1 (es) Propeptido bmp-11 modificado en el residuo 98 de una secuencia bmp-11 humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; metodo para preparar el propeptido, celula recombinante; uso del propeptido para tratar desordenes musculares, neuromusculares, metabolicos, y degenerativos de los huesos (divisional sol.224-02).
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
BRPI0413728B8 (pt) muteína da lipocalina da lágrima humana, métodos para geração e para produção de muteína, composição farmacêutica e uso de muteína
CL2019003405A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
CY1109207T1 (el) Διαδικασια εχινοκανδινης
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
BRPI0407649A (pt) formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação
WO2004085466A8 (en) Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
DE60125528D1 (de) Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung
WO2003095480A3 (en) Brachyspira hyodysenteriae vaccine
BR0009775A (pt) Método para melhorar a migração e invasão de mioblastos no contexto de terapia genética
WO2004007726A3 (en) Brachyspira hyodysenteriae vaccine
ZA200602107B (en) Piroplasmid vaccine
BRPI0407601A (pt) molécula de ácido nucleico, plasmìdeo, composição farmacêutica, uso de nmolécula de ácido nucleico, e método de tratamento ou de prevenção de tumores
BR0211346A (pt) Método para produzir um polipeptìdeo, e, precursor de polipeptìdeo para um polipeptìdeo desejado
DE60329862D1 (de) Rre und cte umfassende gentechnische konstrukte und zusammensetzungen und verwendungen davon
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen

Legal Events

Date Code Title Description
FB Suspension of granting procedure